|
Sep 3
|
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
|
|
Jun 14
|
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
|
|
May 13
|
We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
|
|
May 7
|
Cogent Biosciences Reports First Quarter 2024 Financial Results
|
|
Apr 9
|
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
|
|
Feb 14
|
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
|
|
Jan 9
|
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
|
|
Jan 2
|
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 9
|
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
|
|
Dec 7
|
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
|
|
Dec 4
|
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
|
|
Nov 29
|
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
|
|
Nov 27
|
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans?
|